Crossref
Chronic Myeloid Leukemia: Where Do We Go Now?
Clinical Lymphoma and Myeloma · 2009-12 · 9 · S374-S375
DOI: 10.3816/clm.2009.s.036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma and Myeloma, 2009-12. Verfasst von Jorge E Cortés. Beteiligte Einrichtung: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, USA. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Antineoplastic AgentsBenzamidesHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositivePiperazinesProtein Kinase InhibitorsPyrimidinesRemission InductionSurvival Rate
Substanzen
Antineoplastic AgentsBenzamidesPiperazinesProtein Kinase InhibitorsPyrimidinesImatinib Mesylate
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, USA.
Zitieren
APA
Cortés, J. E. (2009). Chronic Myeloid Leukemia: Where Do We Go Now?. Clinical Lymphoma and Myeloma, 9, S374-S375. https://doi.org/10.3816/clm.2009.s.036
Vancouver
Cortés JE. Chronic Myeloid Leukemia: Where Do We Go Now?. Clinical Lymphoma and Myeloma. 2009;9:S374-S375. doi:10.3816/clm.2009.s.036
BibTeX
@article{Corts2009,
author = {Cortés, Jorge E},
title = {Chronic Myeloid Leukemia: Where Do We Go Now?},
journal = {Clinical Lymphoma and Myeloma},
year = {2009},
volume = {9},
pages = {S374--S375},
doi = {10.3816/clm.2009.s.036}
}
EUVIMED